Key Record Dates Identifier: NCT04433546
Brief Title: Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)

First Submitted : May 28, 2020
First Submitted that Met QC Criteria : June 13, 2020
First Posted : June 16, 2020

Last Update Submitted that Met QC Criteria : December 9, 2020
Last Update Posted : December 11, 2020